Search Results - subject:"Thromboembolism"

An Artificial Intelligence Approach to Thrombophilia Risk

Vilhena, João; Vicente, Henrique; Martins, M. Rosário; … - In: International Journal of Reliable and Quality … 6 (2017) 2, pp. 49-69

. Venous thromboembolism, represented mainly by deep venous thrombosis and pulmonary embolism, is often a chronic illness …

Persistent link: https://www.econbiz.de/10012047316

ЭКОЛОГИЯ ДИРОФИЛЯРИОЗА СОБАК И МОРФОФУНКЦИОНАЛЬНАЯ ДИНАМИКА ЕГО ОСЛОЖНЕНИЯ ТРОМБОЭМБОЛИЕЙ ЛЕГОЧНОЙ АРТЕРИИ

НИКОЛАЕВИЧ, ШИНКАРЕНКО … - In: Вестник Волгоградского … (2009) 3, pp. 233-237

Определена и изучена экология дирофиляриоза и морфофункциональные изменения по результатам исследований электрокардиографии (ЭКГ), рентгенографии грудной...

Persistent link: https://www.econbiz.de/10011246831

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective

Duran, Aurea; Sengupta, Nishan; Diamantopoulos, Alexander; … - In: PharmacoEconomics 30 (2012) 2, pp. 87-101

), is associated with an increased risk of venous thromboembolism (VTE). Abstract: Objective:Objective: Clinical trials have …

Persistent link: https://www.econbiz.de/10010614296

Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal

Holmes, Michael; Carroll, Christopher; Papaioannou, Diana - In: PharmacoEconomics 30 (2012) 2, pp. 137-146

venous thromboembolism (VTE) in adult patients who have undergone total hip replacement (THR) or total knee replacement (TKR …

Persistent link: https://www.econbiz.de/10010614405

Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting

McCullagh, Laura; Walsh, Cathal; Barry, Michael - In: PharmacoEconomics 30 (2012) 10, pp. 941-959

etexilate and enoxaparin sodium for the prophylaxis of venous thromboembolism after total hip replacement. The expected value of …

Persistent link: https://www.econbiz.de/10010569818

Warfarin Pharmacogenetics: Economic Considerations

Hughes, Dyfrig A.; Pirmohamed, Munir - In: PharmacoEconomics 25 (2007) 11, pp. 899-902

Persistent link: https://www.econbiz.de/10005590389

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients: Modelling Study from the Hospital Perspective in Germany

Schadlich, Peter K.; Kentsch, Michael; Weber, Manfred; … - In: PharmacoEconomics 24 (2006) 6, pp. 571-591

from the MEDENOX (prophylaxis in MEDical patients with ENOXaparin) and the THE-PRINCE (THromboEmbolism-PRevention IN …

Persistent link: https://www.econbiz.de/10004990355

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis

Dranitsaris, George; Vincent, Mark; Crowther, Mark - In: PharmacoEconomics 24 (2006) 6, pp. 593-607

Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis … of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52 …

Persistent link: https://www.econbiz.de/10005590421

Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis

Gomez-Outes, Antonio; Rocha, Eduardo; … - In: PharmacoEconomics 24 (2006) 1, pp. 81-92

Introduction: Low-molecular-weight heparins (LMWHs) are at least as effective and well tolerated as unfractionated heparin (UFH) in the treatment of deep vein thrombosis (DVT), offering easier administration and obviating the need for anticoagulant monitoring, but have a higher acquisition cost...

Persistent link: https://www.econbiz.de/10005449200

Cost Effectiveness of Dalteparin for Preventing Venous Thromboembolism in Abdominal Surgery

Heerey, Adrienne; Suri, Sanjeev - In: PharmacoEconomics 23 (2005) 9, pp. 927-944

the incidence of venous thromboembolism (VTE) in these patients. Dalteparin may be used in low (2500 units [U]) and high …

Persistent link: https://www.econbiz.de/10005404949